Assertio Therapeutics Enters Into $3.6M Off-Label False Claims Settlement

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

By signing up for a tour of the Thompson FDA Compliance Expert Suite, you are also registering to receive email offers and product updates from us. Simply click unsubscribe at the bottom of any email if you would like to discontinue delivery.

Assertio Therapeutics Enters Into $3.6M Settlement To Resolve Off-Label False Claims Allegations

Dennis Tosh

May 14, 2025 at 03:09 PM EST

An Illinois-based drug company will pay $3.6 million to resolve allegations that it violated the False Claims Act by causing health care providers to submit fraudulent reimbursement claims to federal health care programs for off-label uses of a fentanyl drug (United States ex rel. Webb v. Depomed, Inc., No. 1:17-cv-02309-JDB (D.D.C.)). Assertio Therapeutics Inc., formerly kno... Read More

My Research Folders

You are not Logged in yet, Please login to see Your research folders.

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

Assertio Therapeutics Enters Into $3.6M Settlement To Resolve Off-Label False Claims Allegations

My Research Folders

THOMPSON FDA

COMPLIANCE EXPERT

RESOURCES

HELP

CONTACT